Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 37.0% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 625,928 shares of the medical equipment provider's stock after acquiring an additional 168,889 shares during the quarter. Wedge Capital Management L L P NC owned about 0.28% of Hologic worth $38,664,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC boosted its position in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares during the last quarter. Smithfield Trust Co boosted its holdings in shares of Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 400 shares during the last quarter. Finally, Raiffeisen Bank International AG acquired a new stake in shares of Hologic in the fourth quarter worth $49,000. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Price Performance

NASDAQ:HOLX traded down $0.56 during trading hours on Wednesday, hitting $64.58. 2,740,609 shares of the stock were exchanged, compared to its average volume of 2,304,520. The firm's fifty day moving average price is $58.42 and its 200 day moving average price is $65.16. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The company has a market cap of $14.39 billion, a P/E ratio of 20.37, a P/E/G ratio of 2.14 and a beta of 0.55. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. During the same period in the previous year, the business earned $1.03 earnings per share. The firm's revenue for the quarter was down 1.2% on a year-over-year basis. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on HOLX. Evercore ISI decreased their target price on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Stephens lowered their target price on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Raymond James reaffirmed an "outperform" rating and set a $71.00 target price (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Finally, Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Hologic presently has a consensus rating of "Hold" and a consensus target price of $77.42.

Insider Transactions at Hologic

In other Hologic news, Director Martin D. Madaus acquired 5,445 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The stock was bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the purchase, the director now owns 5,445 shares in the company, valued at approximately $300,781.80. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.88% of the company's stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.